Background
==========

Tuberculosis (TB) is a serious global health problem, with the largest number of cases disproportionately occurring in developing countries. The Philippines is one of the countries hardest hit by the disease, with the second highest TB incidence in Asia \[[@B1]\]. We previously reported a remarkably high prevalence of 12.8% for TB disease and 65.6% for TB infection among household contacts of tuberculosis patients in the Philippines \[[@B2]\]. The Philippines also bear a significant proportion of the global multidrug resistant (MDR) TB burden \[[@B3],[@B4]\]. Although the Philippines have an extremely high rate of TB, little is known about *M tuberculosis* genotype and transmission dynamics in this country. The aim of this study was to determine the proportion of household contacts who develop active TB due to direct transmission from an index case in that household.

Molecular genotyping has advanced the understanding of *M tuberculosis* transmission and is helpful in identifying transmission links in a community. Restriction fragment-length polymorphism (RFLP) analysis of the insertion sequence 6110 (IS6110) is often used for genotyping of *M tuberculosis*. However, molecular characterization using RFLP method is laborious and requires culture for several weeks to obtain large quantities of genomic DNA. In addition, RFLP has poor discriminatory power for isolates with low numbers of insertion sites \[[@B5]\]. The development of PCR-based typing methods has enabled rapid mycobacterial genotyping \[[@B6],[@B7]\]. Spacer oligonucleotide typing (spoligotyping) is a rapid PCR-based method that examines DNA polymorphisms at the unique direct repeat (DR) region of *M tuberculosis*. It is easier to perform and requires smaller amounts of DNA than RFLP analysis but its discriminatory capacity is inferior to RFLP. Spoligotyping is useful in discriminating strains with low IS6110 copy numbers and it can be performed on nonviable organisms. Mycobacterial interspersed repetitive units (MIRU) -- variable number tandem repeats (VNTR) is another PCR-based method that is easily reproducible and does not require extensive DNA purification. MIRU-VNTR \[[@B8]\] has become a major method for rapid, high-resolution genotyping of *M tuberculosis* complex isolates. The method relies on PCR amplification of multiple loci (12, 15 or 24 loci) using primers specific for the flanking regions of each repeat locus and on the determination of the sizes of the amplicons, which reflect the numbers of the targeted MIRU-VNTR copies \[[@B9]\]. Moreover, the results are expressed as numerical codes and are therefore easy to compare and exchange between laboratories \[[@B10]\].

Only a limited number of *M tuberculosis* isolates from the Philippines have been genotyped \[[@B11],[@B12]\]; no studies have described the epidemiologic links among isolates. The aims of this study were to characterize *M tuberculosis* isolated from TB patients in Philippine households using three methods for genotyping, namely RFLP, spoligotyping, and MIRU-VNTR, and to describe the transmission and drug susceptibility patterns of these isolates.

Methods
=======

Study isolates
--------------

Sputum for acid-fast bacilli (AFB) smear microscopy and culture were collected from the index case (IC) and household contact (HC) cases during a contact investigation study on sputum smear-positive TB patients seen at the Tropical Disease Foundation DOTS Clinic, Makati Medical Center, Metro Manila between 2001 and 2003 \[[@B2],[@B13]\]. Two hundred eighteen index cases aged ≥18 years with sputum smear-positive TB, including 163 (74.8%) with MDR-TB, were identified. Eight hundred ninety seven of their household contacts were evaluated for TB with tuberculin skin test, chest x-ray and sputum examination. One hundred thirteen (12.8%) household contacts with TB were identified by positive chest x-rays and/or positive sputum results; of these, 20 were sputum culture-positive. A total of 29 *M tuberculosis* paired isolates were available from 13 index patients and 16 household contacts. Patients were between the ages of 10 and 60 (mean, 31) years; eight were females, 21 were males.

All sputum specimens were first processed and cultured on Lowenstein-Jensen slants and strain identification was performed in the Philippines using the nitrate and niacin tests according to established protocols \[[@B14]\]. The identification of the isolates was confirmed in the United States prior to genotyping studies using a nucleic acid hybridization probe specific for *M. tuberculosis* complex (GenProbe AccuProbe®, San Diego, CA). Antimicrobial susceptibility testing was performed in the Philippines and confirmed in the United States using Clinical and Laboratory Standards Institute guidelines \[[@B15]\] with the 1% indirect agar proportion method used for all antimicrobial agents except pyrazinamide. Pyrazinamide was tested using the VersaTREK broth system (TREK Diagnostics, Cleveland, OH). Isolates were genotyped using RFLP IS6110 fingerprinting \[[@B5]\], spoligotyping \[[@B6]\] and 12-loci MIRU-VNTR typing \[[@B16]\] as previously described.

Ethics statement
----------------

The study was approved by the Institutional Review Boards of Mayo Clinic Rochester and the Tropical Disease Foundation - Makati Medical Center. Written informed consent was obtained from all patients, adult household contacts, and/or head of household.

Results
=======

Genotyping
----------

IS6110 fingerprinting, spoligotyping and 12-loci MIRU-VNTR typing were done on 29 *M tuberculosis* isolates from 13 households in the Philippines (Table [1](#T1){ref-type="table"}). One household had three household contacts with TB; another household had two contacts with TB. Altogether, there were 16 paired IC-HC isolates. Genotyping found 23 IS6110 fingerprints, 9 spoligotypes, and 13 MIRU-VNTR types.

###### 

**IS6110 Restriction fragment length polymorphism (RFLP), spoligotyping, and mycobacterial interspersed repetitive unit variable numbers of tandem repeat (MIRU-VNTR) typing patterns of*Mycobacterium tuberculosis*isolates from index case (IC) and household contact (HC) cases from the Philippines**

  **Household/index group**   **RFLP Pattern**   **Spoligotype pattern**                                     **MIRU-VNTR Code**   **Lineage/family**   **Methods with matching paired IC-HC**   **DST match?**
  --------------------------- ------------------ ----------------------------------------------------------- -------------------- -------------------- ---------------------------------------- ----------------
                                                 **1 Spacer \# 43**                                                                                                                              
  IC1                         5--13              ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   244336223432         Manila                                                         
  HC1                         5--13              ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   244336223432         Manila               RFLP/Spoligo/MIRU                        No
  IC2                         10--14             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223432         Manila                                                         
  HC2                         34--13             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223432         Manila               Spoligo/MIRU                             No
  IC3                         2--13              ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ □□□ □□□ □□■ ■■■ ■■■ ■   254326223432         ND                                                             
  HC3                         2--13              ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ □□□ □□□ □□■ ■■■ ■■■ ■   254326223432         ND                   RFLP/Spoligo/MIRU                        No
  IC4                         35--11             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223422         Manila                                                         
  HC4                         3--12              ■■□ ■■■ ■■■ ■■■ ■□□ □■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223432         ND                   None                                     No
  IC5                         1--13              ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223332         Manila                                                         
  HC5                         1--13              ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223332         Manila               RFLP/Spoligo/MIRU                        Yes
  IC6                         11--15             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   234326223432         Manila                                                         
  HC6.1                       4--16              ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   234326223432         Manila               Spoligo/MIRU (IC6/HC6.1)                 No
  HC6.2                       6--14              ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   234326223432         Manila               Spoligo/MIRU (IC6/HC6.2)                 No
  HC6.3                       7--13              □■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □□□ ■■■ ■■■ ■   253326223432         ND                   None (IC6/HC6.3)                         No
  IC7                         19--12             ■■□ ■■■ ■□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□■ ■■■ ■   254326223432         ND                                                             
  HC7.1                       20--13             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223432         Manila               MIRU (IC7/HC7.1)                         No
  HC7.2                       18--11             ■■□ ■■■ □■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □□■ □■■ ■■■ ■   274326223432         ND                   None (IC7/HC7.1)                         No
  IC8                         12--15             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   234326223432         Manila                                                         
  HC8                         37--13             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223432         Manila               Spoligo                                  No
  IC9                         14--19             □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □■■ ■■■ ■■■ ■   223325173533         Beijing                                                        
  HC9                         14--19             □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □■■ ■■■ ■■■ ■   223325173533         Beijing              RFLP/Spoligo/MIRU                        Yes
  IC10                        27--12             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223422         Manila                                                         
  HC10                        27--12             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223422         Manila               RFLP/Spoligo/MIRU                        Yes
  IC11                        25--15             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ □□□ □□□ □□□ □□□ □□□ □□□ □   254326224332         ND                                                             
  HC11                        23--12             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   254326223432         ND                   MIRU                                     No
  IC12                        32--11             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■■□ □□□ □□□ □□□ ■■□ □□□ ■■■ ■■■ ■   224227163221         ND                                                             
  HC12                        28--13             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■■□ □□□ □□□ □□□ ■■□ □□□ ■■■ ■■■ ■   224227163321         ND                   Spoligo/MIRU                             No
  IC13                        29--11             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   354326223422         Manila                                                         
  HC13                        29--11             ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■   354326223422         Manila               RFLP/Spoligo/MIRU                        No

*RFLP* = restriction fragment length polymorphism; *Spoligo* = spligotyping; *MIRU* = multiple interspersed repeating units/variable number tandem repeats; *ND* = not determined; *IC* = index case; *HC* = household contact patient, *DST* = drug susceptibility.

When known, lineage information is listed.

Isolates had between 11 and 19 (median, 13) copies of IS6110 by RFLP. By spoligotyping, two isolates from one household (Table [1](#T1){ref-type="table"}, IC9 and HC9) had the Beijing genotype and 17 (58.6%) of isolates from nine households lacked eight spacers characteristic of the Manila family \[[@B12]\].

Spoligotyping and MIRU-VNTR typing both matched in 10 (62.5%) of 16 pairs while IS6110 fingerprints matched in only six (37.5%) IC-HC pairs. All six pairs with matching IS6110 fingerprints also matched by spoligotypes and MIRU-VNTR types. Three paired isolates matched by only one genotyping method, and the remaining three pairs had genotypes that were different by all three fingerprinting methods.

Drug susceptibility testing
---------------------------

Results of drug susceptibility testing are shown in Table [2](#T2){ref-type="table"}. Only four of the 29 (13.8%) isolates were fully susceptible to all first line drugs; eight (27.6%) were resistant to all first line drugs. Isoniazid (INH) resistance was detected in 24/29 (82.8%) and 19/29 (65.5%) at low (0.2 μg/ml) and high (1.0 μg/ml) concentrations, respectively. Resistance to rifampin (RIF), ethambutol (EMB) and pyrazinamide (PZA) occurred in 19/29 (65.5%), 14/29 (48.3%), and 9/28 (32.1%), respectively. There were 19 (65.5%) MDR *M tuberculosis* isolates. With second line drugs, resistance to streptomycin (STR) at 2.0 μg/ml, streptomycin at 10 μg/ml, capreomycin (CAP), and ethionamide (ETH) was detected in 16/29 (55.2%), 13/29 (44.8%), 3/29 (10.3%), and 6/29 (20.7%), respectively. Resistance to kanamycin (KAN), amikacin (AMI), cycloserine (CYC) and para-aminosalicylic acid (PAS) was not detected. Because resistance testing to fluoroquinolones was not performed, the number of extensively-drug resistant isolates is not known.

###### 

**Drug susceptibilities of*Mycobacterium tuberculosis*isolates from index case (IC) and household contact (HC) cases in the Philippines**

           **First line drugs**^***a***^   **Second line drugs**                                                 
  ------- ------------------------------- ----------------------- --- --- ---------- --- --- --- --- --- --- --- ---
  IC1                    R                           R             R   R      R       S   S   S   S   S   S   S   S
  HC1                    R                           R             S   S      S       S   S   S   S   S   S   S   S
  IC2                    R                           R             R   R      R       R   R   S   S   S   S   S   S
  HC2                    R                           R             R   S      S       R   R   S   S   S   S   S   S
  IC3                    R                           S             R   S      S       R   R   S   S   S   S   S   S
  HC3                    R                           R             R   S      S       S   S   S   S   S   S   S   S
  IC4                    R                           R             R   S   N/A^*b*^   R   S   S   S   S   R   S   S
  HC4                    R                           R             S   S      S       R   S   S   S   S   S   S   S
  IC5                    R                           R             R   R      R       R   R   S   S   S   S   S   S
  HC5                    R                           R             R   R      R       R   R   S   S   S   S   S   S
  IC6                    R                           R             R   R      R       R   R   S   S   S   R   S   S
  HC6.1                  R                           R             R   R      S       R   R   S   S   S   R   S   S
  HC6.2                  R                           R             R   R      S       R   R   S   S   S   R   S   S
  HC6.3                  S                           S             S   S      S       S   S   S   S   S   S   S   S
  IC7                    R                           S             R   R      S       R   R   S   S   S   R   S   S
  HC7.1                  S                           S             S   S      S       S   S   S   S   S   S   S   S
  HC7.2                  S                           S             S   S      S       S   S   S   S   S   S   S   S
  IC8                    R                           S             S   S      S       S   S   S   S   S   S   S   S
  HC8                    S                           S             S   S      R       S   S   S   S   S   S   S   S
  IC9                    R                           R             R   R      R       R   R   S   S   S   S   S   S
  HC9                    R                           R             R   R      R       R   R   S   S   S   S   S   S
  IC10                   R                           S             S   S      S       S   S   S   S   S   S   S   S
  HC10                   R                           S             S   S      S       S   S   S   S   S   S   S   S
  IC11                   S                           S             S   S      S       S   S   S   S   S   S   S   S
  HC11                   R                           R             R   S      S       S   S   R   S   S   R   S   S
  IC12                   R                           R             R   R      R       R   R   R   S   S   S   S   S
  HC12                   R                           R             R   R      S       R   R   R   S   S   S   S   S
  IC13                   R                           R             R   R      S       R   S   S   S   S   S   S   S
  HC13                   R                           R             R   R      S       S   S   S   S   S   S   S   S

Susceptibilities are reported in μg/mL.

Abbreviations: *INH* -- isoniazid, *RIF* -- rifampin, *EMB* -- ethambutol, *PZA* -- pyrazinamide, *STR* -- streptomycin, *CAP* -- capreomycin, *KAN* -- kanamycin, *AMI* -- amikacin, *ETH* -- ethionamide, *CYC* -- cycloserine, *PAS* -- para-aminosalicylic acid; *R* -- resistant, *S* -- susceptible.

^*a*^With the exception of PZA, susceptibility for all drugs was performed by the 1% indirect agar proportion method. PZA susceptibility was performed on the VersaTREK (TREK Diagnostics, Cleveland, OH).

^*b*^Isolate unable to grow in test medium for PZA susceptibility testing.

Comparing test results of paired IC-HC isolates, only 3/16 (18.8%) had identical drug susceptibility results. In one household with four cases of TB (IC6), only two isolates had the same susceptibility pattern. Both isolates with the Beijing genotype were multidrug resistant, whereas 11 of 17 (64.7%) isolates with the Manila genotype were multidrug resistant.

Discussion
==========

DNA fingerprinting of *M tuberculosis* has transformed our understanding of the transmission of TB and provides a tool for the identification of transmission patterns. We sought to better understand TB transmission in the Philippines, which has a high TB and MDR TB burden, by molecular characterization of *M tuberculosis* isolates from household contacts of TB cases. Using three genotyping methods, our results show that based on the highest level of discrimination by IS6110 fingerprinting, approximately two-thirds (10/16, 62.5%) of TB in household contacts may have been acquired from a source outside of the household. A number of studies have elucidated that household contacts of TB patients have a higher risk of being infected \[[@B17]-[@B20]\]. In high TB prevalence setting, there are multiple sources of infection and numerous opportunities for TB transmission as a result of social mixing \[[@B21]\].

In Capetown, South Africa, where TB is highly endemic, RFLP analysis of 313 isolates from 129 households showed matching fingerprints in only 46%; the authors estimated that proportion of TB transmission occurring in household is only 19% \[[@B22]\]. Metro Manila is the largest city in the Philippines, with a population of over 11 million people, and a large number of urban poor settlements where TB is a substantial problem \[[@B23]\]. We analyzed *M tuberculosis* isolates that were collected from index and household contact TB cases in Metro Manila. IS6110 genotypes from household contacts matched those of index cases in six of 16 (37.5%). In the two households with more than two TB cases (IC6 and IC7), none of the isolates from the same household matched in IS6110 fingerprint. The fact that individuals with TB from the same household are infected with different strains of *M tuberculosis* suggests that the infection was acquired from outside the household, and most likely reflects the TB burden in the community.

Very few studies have been done to molecularly characterize *M tuberculosis* isolates from the Philippines. Analysis of 40 randomly collected isolates from the Philippines revealed that 38 of isolates had 80% or greater similarity, but non-identical, IS6110 fingerprints; these isolates has been given the designation as the Manila family \[[@B12]\]. In another study, 33 of 34 (97.0%) isolates from the Philippines also collected at random, showed similar but distinct IS6110 fingerprints \[[@B11]\]*. These* isolates had more than eight copies of IS6110, most having 13 copies. Our findings corroborate the presence of different strains of *M tuberculosis* with 11 or greater copies of IS6110 circulating in the community.

Spoligotyping of 48 *M tuberculosis* isolates from Manila showed patterns that were highly similar; 41/48 (85.4%) had identical patterns lacking hybridization to eight spacers \[[@B12]\]. These isolates have been classified as the Manila family. In our study on 29 isolates, 17 (58.6%) lacked hybridization to these spacers.

In The Gambia, spoligotyping on nine paired index-household cases revealed six (66.6%) pairs to match and three (33.3%) that were unmatched \[[@B24]\]. Our results showed a similar rate of spoligotype matching in 11 of 16 (68.8%) pairs. In the Philippines where most isolates of *M tuberculosis* have ≥8 copies of IS6110 \[[@B12]\], spoligotyping does not appear to be sufficiently discriminatory as an epidemiologic tool. We detected the same number of matched isolates (11/16) with MIRU-VNTR as spoligotyping.

IS6110 RFLP typing \[[@B25]\] has been replaced in some settings with easier-to-perform, alternative PCR-based strategies, such as spoligotyping and MIRU-VNTR. These alternative typing methods, with classical epidemiological investigations, are being internationally adopted as the new reference method for TB molecular epidemiology \[[@B26],[@B27]\]. A recent population-based study indicated that the use of MIRU-VNTR system as a first-line method in combination with spoligotyping provides adequate discrimination in most cases for large-scale, prospective genotyping of *M. tuberculosis* in the United States \[[@B28]\]. However, IS*6110* fingerprinting is still useful as an additional method to type the clustered isolates in a number of cases. The combination of these two PCR-based typing methods may be useful in low TB prevalence settings \[[@B28]\], but its utility in high TB prevalence settings has yet to be clearly demonstrated. In our sample of 16 paired isolates for example, the combination of spoligotyping and MIRU-VNTR typing matched 10 pairs of isolates, whereas IS6110 fingerprinting further discriminated the isolates into only six matching pairs.

We tested a high number of MDR *M tuberculosis* isolates; this was expected since we identified patients at a referral center for treatment of MDR TB \[[@B29]\]. Comparing fingerprint data with drug susceptibility results, only three of the six (50.0%) pairs with identical genotypes had matching drug susceptibility. There were no observable patterns in terms of the matched isolates being from a particular type of household relationship (eg., the young child or the partner of an index case) or in the length of time between diagnosis of the index patient and the household contact(s) (Table [3](#T3){ref-type="table"}). Since 10 of 13 index patients had MDR-TB, we were unable to determine whether MDR-TB patients were more likely to transmit TB to a household contact than the non-MDR index patients. These finding have implications in the treatment of TB and highlight the importance of drug susceptibility testing; treatment of TB in household contacts cannot be inferred from drug susceptibility of *M tuberculosis* of index patients.

###### 

Patient demographics

   **Index patient/ pousehold contact(s)**   **Year diagnosed with tuberculosis**   **Years between diagnosis**   **Age at diagnosis**   **Sex**   **Relationship**   **DST matches? (Y/N)**   **Genotyping match?**^**a**^**(Y/N)**
  ----------------------------------------- -------------------------------------- ----------------------------- ---------------------- --------- ------------------ ------------------------ ---------------------------------------
                     IC1                                     2001                                                          41               F                                                                     
                     HC1                                     2001                                0                         22               F           child                   N                                Y
                     IC2                                     2001                                                          28               M                                                                     
                     HC2                                     2001                                0                         18               M          sibling                  N                                N
                     IC3                                     2001                                                          52               M                                                                     
                     HC3                                      NA                                NA                         22               F           child                   N                                Y
                     IC4                                     2001                                                          38               M                                                                     
                     HC4                                     2001                                0                         10               M           child                   N                                N
                     IC5                                     2001                                                          42               M                                                                     
                     HC5                                     2001                                0                         22               M           child                   Y                                Y
                     IC6                                     2002                                                          17               M                                                                     
                    HC6.1                                    2002                                0                         20               M          sibling                  N                                N
                    HC6.2                                    2002                                0                         29               M          sibling                  N                                N
                    HC6.3                                    2002                                0                         22               M          sibling                  N                                N
                     IC7                                     2002                                                          43               M                                                                     
                    HC7.1                                    2002                                0                         33               F          sibling                  N                                N
                    HC7.2                                     NA                                NA                         41               M          sibling                  N                                N
                     IC8                                     2001                                                          28               F                                                                     
                     HC8                                     2007                                6                         60               M           parent                  N                                N
                     IC9                                     2001                                                          19               M                                                                     
                     HC9                                     2003                                2                         30               M          sibling                  Y                                Y
                    IC10                                     2000                                                          40               M                                                                     
                    HC10                                     2003                                3                         40               F          sibling                  Y                                Y
                    IC11                                     2003                                                          NA               M                                                                     
                    HC11                                     2004                                1                         NA               M             NA                    N                                N
                    IC12                                     2003                                                          30               F                                                                     
                    HC12                                     2004                                1                         28               F          sibling                  N                                N
                    IC13                                     2003                                                          49               M                                                                     
                    HC13                                     2008                                5                         32               M           child                   N                                Y

*DST* = drug susceptibility testing, *NA* = not available, *Y* = yes, *N* = no.

^a^Using all 3 methods (spoligotyping, MIRU-VNTR and RLFP).

Our study has some limitations. We tested only a small number of isolates, and samples were collected from a TB referral center in one geographic area in the Philippines. Our results may not reflect the predominantly circulating strains of *M tuberculosis* in the general population. Lately, MIRU-VNTR typing of 15 or 24 loci has been applied to molecular typing of *M tuberculosis*; we may have found more genetic diversity in our samples with 24-loci method than with the 12-loci method used in this study. Nonetheless, our data demonstrate that there is significant genotype and drug susceptibility diversity within households with multiple cases of tuberculosis.

Conclusions
===========

Patients in high TB burden regions are exposed to TB outside the home, and therefore may be infected by source patients outside the home. Genotyping of *M tuberculosis* from the Philippines will aid in understanding the epidemiology of TB of this country, which can lead to improved strategies to reduce TB prevalence in the country.

Our results augment the findings from other studies that in highly prevalent areas, TB transmission is as likely to occur in the community as it is within the household. Furthermore, our data highlights the importance of drug susceptibility testing particularly for household contacts of MDR TB patients to ensure that they receive the appropriate drugs to which their isolates are susceptible. Our results have significant implications to TB control in the Philippines. Strain typing of TB provides valuable information on the number and type of strains circulating in a community; more importantly, it provides information on the transmission, which informs prevention and control. Further studies on a larger number of isolates are needed to properly elucidate the epidemiology and transmission of TB in this country.
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